Medicament

Abstract

To provide a technique for suppressing freezing of a ripasudil-containing aqueous composition stored in a polyolefin resin-made vessel and having an amount of oxygen dissolved of ≥ 8. 5mg / L when stored at a low temperature.SOLUTION: A pharmaceutical preparation in which an aqueous composition containing ripasudil or salts thereof or solvates thereof and lower aliphatic carboxylic acids and having an amount of dissolved oxygen of 8. 5mg / L or more is contained in a polyethylene vessel.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to pharmaceutical preparations and the like. [Background technology]

[0002] The following structural formula:

[0003] [ka]

[0004] Ripasudil (chemical name: 4-fluoro-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline) represented by the formula (I) has pharmacological effects such as Rho kinase inhibitory activity (e.g., Patent Document 1), and is known to be useful for the prevention and treatment of ocular diseases. Specifically, it has been reported to be useful for the prevention or treatment of ocular hypertension, glaucoma, and the like (e.g., Patent Document 2), or for the prevention or treatment of ocular fundus diseases such as age-related macular degeneration (e.g., Patent Document 3). Furthermore, "Glanatec" (registered trademark) and "Glaalpha" (registered trademark), which contain ripasudil hydrochloride hydrate as an active ingredient, have been developed and marketed in several countries, including Japan, as agents for the prevention and treatment of ocular hypertension and glaucoma (Non-Patent Documents 1 and 2). Therefore, it would be extremely useful to establish a technique for stably formulating Ripasudil as, for example, an ophthalmic agent.

[0005] It has been reported that discoloration after long-term storage at high temperatures can be suppressed by storing an aqueous composition containing Ripasudil, a salt thereof, or a solvate thereof in a container made of a polyolefin resin such as polyethylene or polypropylene (Patent Document 4). Furthermore, both Glanatec and Glaalpha are pharmaceuticals in which an aqueous composition containing Ripasudil hydrochloride hydrate is contained in a polypropylene eye drop container body. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Patent No. 4212149 [Patent Document 2] International Publication No. 2006 / 068208 Pamphlet [Patent Document 3] Patent No. 5557408 [Patent Document 4] Patent No. 6244038 [Non-patent literature]

[0007] [Non-Patent Document 1] Pharmaceutical interview form "Glanatec (registered trademark) eye drops 0.4%" Kowa Company, Ltd., September 2023 [Non-patent document 2] Pharmaceutical interview form "Gla Alpha (registered trademark) combination eye drops," Kowa Company, Ltd., June 2024 Summary of the Invention [Problem to be solved by the invention]

[0008] Ophthalmic preparations and the like are usually compositions containing water (aqueous compositions). Therefore, the present inventors investigated the storage stability of aqueous compositions containing Ripasudil, a salt thereof, or a solvate thereof (hereinafter, sometimes referred to as "Ripasudil-containing aqueous compositions"). However, when an investigation was conducted into the case where a Ripasudil-containing aqueous composition was stored in a polyolefin resin container, it was found that while no problems occurred when the composition was stored at room temperature (1 to 30°C), a problem occurred in that the aqueous composition could freeze over time when stored at temperatures as low as -5°C, and when the amount of dissolved oxygen in the Ripasudil-containing aqueous composition was 8.5 mg / L or more.

[0009] This problem can be solved, for example, by adjusting the dissolved oxygen content of the Ripasudil-containing aqueous composition to a low level. In this regard, methods such as substituting dissolved oxygen with an inert gas by nitrogen purging or vacuum degassing can be considered to adjust the dissolved oxygen content of the Ripasudil-containing aqueous composition to a low level. However, implementing these methods requires a great deal of effort and cost. Therefore, an object of the present invention is to provide a technology for preventing freezing of a Ripasudil-containing aqueous composition that is contained in a polyolefin resin container and has a dissolved oxygen content of 8.5 mg / L or more during low-temperature storage. [Means for solving the problem]

[0010] The present inventors have conducted further intensive research to solve the above-mentioned problems and have found that freezing during low-temperature storage is specifically suppressed when a Ripasudil-containing aqueous composition having a dissolved oxygen content of 8.5 mg / L or more further contains a lower aliphatic carboxylic acid represented by one or more selected from the group consisting of edetic acid, its salts, and solvates thereof, and when the aqueous composition is stored in a polyolefin resin container, particularly a polyethylene container, and thus the present invention has been completed.

[0011] That is, the present invention provides a pharmaceutical preparation comprising an aqueous composition containing ripasudil or a salt thereof or a solvate thereof and a lower aliphatic carboxylic acid, the aqueous composition having a dissolved oxygen content of 8.5 mg / L or more, and the aqueous composition being contained in a polyethylene container. The present invention also provides a method for suppressing freezing of an aqueous composition, comprising the steps of adding lower aliphatic carboxylic acids to an aqueous composition containing Ripasudil or a salt thereof, or a solvate thereof and having a dissolved oxygen content of 8.5 mg / L or more, and placing the aqueous composition in a polyethylene container. Furthermore, the present invention provides a method for producing a pharmaceutical preparation in which freezing of the aqueous composition is inhibited, the method comprising the steps of adding lower aliphatic carboxylic acids to an aqueous composition containing Ripasudil or a salt thereof, or a solvate thereof and having a dissolved oxygen content of 8.5 mg / L or more, and placing the aqueous composition in a polyethylene container. [Effects of the Invention]

[0012] According to the present invention, it is possible to prevent freezing of a Ripasudil-containing aqueous composition that is contained in a polyolefin resin container and has a dissolved oxygen content of 8.5 mg / L or more during low-temperature storage. DETAILED DESCRIPTION OF THE INVENTION

[0013] As used herein, "w / v %" refers to mass to volume percentage, specifically the mass (g) of each component contained per 100 mL of the composition.

[0014] <Ripasudil or its salt or solvate> In the present invention, Ripasudil (chemical name: 4-fluoro-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline) may be a salt. The salt of Ripasudil is not particularly limited as long as it is a pharmaceutically acceptable salt, and specific examples thereof include inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrofluoride, and hydrobromide; and organic acid salts such as acetate, tartrate, lactate, citrate, fumarate, maleate, succinate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, naphthalenesulfonate, and camphorsulfonate, with hydrochloride being preferred. Furthermore, Ripasudil or a salt thereof may be a solvate such as a hydrate or an alcohol solvate, and is preferably a hydrate.

[0015] In the present invention, Ripasudil or its salt or a solvate thereof is more preferably Ripasudil or its hydrochloride or a hydrate thereof, and is represented by the following structural formula:

[0016] [ka]

[0017] Ripasudil hydrochloride hydrate (Ripasudil monohydrochloride dihydrate) represented by the following formula is particularly preferred.

[0018] Ripasudil, a salt thereof, or a solvate thereof is known and can be produced by known methods. Specifically, for example, Ripasudil, a salt thereof, or a solvate thereof can be produced by the methods described in WO 1999 / 020620 and WO 2006 / 057397.

[0019] The content of Ripasudil or a salt thereof, or a solvate thereof in the aqueous composition is not particularly limited and may be determined appropriately depending on the disease to be treated, the patient's sex, age, symptoms, etc., but from the viewpoint of obtaining an excellent pharmacological effect, the content may be 0.01 w / v% or more, preferably 0.02 w / v% or more, and more preferably 0.04 w / v% or more, calculated as the free form of Ripasudil, relative to the total volume of the aqueous composition, and may be 10 w / v% or less, preferably 8 w / v% or less, and particularly preferably 6 w / v% or less. Among these, from the viewpoint of obtaining an excellent pharmacological effect, the content of Ripasudil or a salt thereof, or a solvate thereof, calculated as the free form, relative to the total volume of the aqueous composition is preferably 0.05 to 5 w / v%, more preferably 0.1 to 3 w / v%, even more preferably 0.1 to 2 w / v%, and particularly preferably 0.3 to 0.5 w / v%.

[0020] <Lower aliphatic carboxylic acids> In the present invention, the term "lower aliphatic carboxylic acids" refers to one or more compounds selected from the group consisting of lower aliphatic carboxylic acids in which one or more carbon atoms may be replaced by nitrogen atoms, and salts thereof (for example, alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts, etc.), and solvates thereof (hydrates, etc.). Here, the number of carbon atoms in the lower aliphatic carboxylic acids is not particularly limited as long as it is about 15 or less, but from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, it is preferably 2 to 12, more preferably 4 to 12, and particularly preferably 6 to 12. Of these carbon atoms, some of the carbon atoms other than those constituting the carboxyl group may be substituted with nitrogen atoms, but from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, it is preferable that the number of nitrogen atoms substituted is 1 to 2. Furthermore, the carbon chain may be linear or branched, and may be saturated or unsaturated.

[0021] The number of carboxyl groups in the lower aliphatic carboxylic acids is not limited, but from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, it is preferably 1 to 4. Furthermore, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, the lower aliphatic carboxylic acids may further have about 1 to 3 hydrophilic substituents other than carboxyl groups. Specific examples of such hydrophilic substituents include hydroxyl groups and amino groups. The lower aliphatic carboxylic acids are known compounds, and may be produced by known methods or may be commercially available. The lower aliphatic carboxylic acids may form salts or complexes with other components, and aqueous compositions containing components that form such salts or complexes are also included in the "aqueous composition containing a lower aliphatic carboxylic acid."

[0022] Specific examples of such lower aliphatic carboxylic acids include adipic acid; one or more selected from the group consisting of aspartic acid, salts thereof such as aspartic acid, sodium L-aspartate, and magnesium L-aspartate, and solvates thereof; one or more selected from the group consisting of epsilon-aminocaproic acid, salts thereof, and solvates thereof; edetic acid, calcium sodium edetate hydrate, sodium edetate hydrate, tetrasodium edetate hydrate, anhydrous disodium edetate, etc. one or more selected from the group consisting of edetic acid, its salts, and solvates thereof; one or more selected from the group consisting of citric acid, calcium citrate, citric acid hydrate, sodium citrate hydrate, sodium dihydrogen citrate, disodium citrate, anhydrous citric acid, anhydrous sodium citrate, and its salts, and solvates thereof; one or more selected from the group consisting of succinic acid, monosodium succinate, disodium succinate hexahydrate, and other succinic acid, salts, and solvates thereof; acetic acid, One or more selected from the group consisting of acetic acid and its salts, such as ammonium acetate, potassium acetate, calcium acetate, sodium acetate hydrate, glacial acetic acid, and anhydrous sodium acetate, as well as solvates thereof; one or more selected from the group consisting of tartaric acid, D-tartaric acid, potassium hydrogen tartrate, DL-sodium tartrate, and potassium sodium tartrate, as well as salts thereof, and solvates thereof; one or more selected from the group consisting of sorbic acid, such as sorbic acid and potassium sorbate, as well as salts thereof, and solvates thereof; lactic acid, sodium lactate one or more selected from the group consisting of lactic acid, its salts such as propionic acid, sodium propionate, and solvates thereof, and solvates thereof; one or more selected from the group consisting of fumaric acid, its salts, and solvates thereof; one or more selected from the group consisting of maleic acid, its salts, and solvates thereof; one or more selected from the group consisting of malonic acid, its salts, and solvates thereof;Examples thereof include one or more selected from the group consisting of malic acid, DL-malic acid, malic acid such as sodium DL-malate, salts thereof, and solvates thereof, which may be used alone or in combination of two or more. These lower aliphatic carboxylic acids are all known and may be produced by known methods, or commercially available products may be used.

[0023] From the viewpoint of preventing freezing of the Ripasudil-containing aqueous composition during low-temperature storage, the lower aliphatic carboxylic acids are preferably one or more selected from the group consisting of epsilon-aminocaproic acid, edetic acid, citric acid, acetic acid, sorbic acid, their salts, and solvates thereof, more preferably one or more selected from the group consisting of epsilon-aminocaproic acid, edetic acid, their salts, and solvates thereof, and particularly preferably one or more selected from the group consisting of edetic acid, its salts, and solvates thereof. By using one or more selected from the group consisting of edetic acid, its salts, and solvates thereof as the lower aliphatic carboxylic acid, freezing of the Ripasudil-containing aqueous composition during low-temperature storage is significantly prevented compared to other lower aliphatic carboxylic acids.

[0024] The content of lower aliphatic carboxylic acids in the aqueous composition is not particularly limited, but from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, it may contain 0.001 w / v or more, preferably 0.01 w / v% or more, more preferably 0.05 w / v% or more, and particularly preferably 0.1 w / v% or more, relative to the total volume of the aqueous composition, and may contain 5 w / v% or less, preferably 3.5 w / v% or less, and particularly preferably 1 w / v%. In particular, when one or more types selected from the group consisting of epsilon-aminocaproic acid and its salts and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, the content is preferably 0.003 to 3 w / v%, more preferably 0.07 to 1 w / v%, and particularly preferably 0.2 to 0.5 w / v%, relative to the total volume of the aqueous composition. Furthermore, in particular, when one or more types selected from the group consisting of edetic acid, its salts, and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, the content is preferably 0.0003 to 0.3 w / v%, more preferably 0.007 to 0.2 w / v%, and particularly preferably 0.02 to 0.1 w / v%, relative to the total volume of the aqueous composition. Furthermore, in particular, when one or more types selected from the group consisting of citric acid, its salts, and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, the content is preferably 0.006 to 2 w / v%, more preferably 0.04 to 0.4 w / v%, and particularly preferably 0.07 to 0.2 w / v%, relative to the total volume of the aqueous composition. Furthermore, in particular, when one or more types selected from the group consisting of acetic acid, its salts, and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, the content is preferably 0.003 to 2 w / v%, more preferably 0.03 to 0.3 w / v%, and particularly preferably 0.07 to 0.2 w / v%, relative to the total volume of the aqueous composition. Furthermore, in particular, when one or more types selected from the group consisting of sorbic acid and its salts and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, the content is preferably 0.02 to 0.8 w / v%, more preferably 0.09 to 0.4 w / v%, and particularly preferably 0.07 to 0.2 w / v%, relative to the total volume of the aqueous composition.

[0025] Furthermore, the mass ratio of Ripasudil or its salt or solvate thereof to lower aliphatic carboxylic acids in the aqueous composition is not particularly limited, but from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, the composition may contain 0.001 mass parts or more, preferably 0.01 mass parts or more, more preferably 0.3 mass parts or more, more preferably 0.6 mass parts or more, and even more preferably 0.8 mass parts or more of lower aliphatic carboxylic acids per mass part of Ripasudil converted to its free form, and may contain 8 mass parts or less, preferably 4 mass parts or less, and particularly preferably 3 mass parts or less. In particular, when one or more types selected from the group consisting of epsilon-aminocaproic acid, its salts, and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, it is preferable to contain 0.05 to 2.5 parts by mass, more preferably 0.2 to 2 parts by mass, and particularly preferably 0.5 to 1.5 parts by mass of one or more types selected from the group consisting of epsilon-aminocaproic acid, its salts, and solvates thereof per part by mass of Ripasudil converted to its free form. Furthermore, in particular, when one or more types selected from the group consisting of edetic acid, its salts, and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, it is preferable to contain 0.003 to 2 parts by mass, more preferably 0.01 to 1 part by mass, and particularly preferably 0.02 to 0.5 parts by mass of one or more types selected from the group consisting of edetic acid, its salts, and solvates thereof per 1 part by mass of Ripasudil converted to its free form. Furthermore, in particular, when one or more types selected from the group consisting of citric acid, its salts, and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, it is preferable to contain 0.003 to 5 parts by mass, more preferably 0.03 to 2 parts by mass, and particularly preferably 0.07 to 7 parts by mass of one or more types selected from the group consisting of citric acid, its salts, and solvates thereof per 1 part by mass of Ripasudil converted to its free form. Furthermore, in particular, when one or more types selected from the group consisting of acetic acid, its salts, and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, it is preferable to contain 0.003 to 2 parts by mass, more preferably 0.03 to 1 part by mass, and particularly preferably 0.02 to 0.8 parts by mass of one or more types selected from the group consisting of acetic acid, its salts, and solvates thereof per 1 part by mass of Ripasudil converted to its free form. Furthermore, in particular, when one or more types selected from the group consisting of sorbic acid and its salts and solvates thereof are used as the lower aliphatic carboxylic acids, from the viewpoint of preventing freezing during low-temperature storage of the Ripasudil-containing aqueous composition, it is preferable to contain 0.04 to 3 parts by mass, more preferably 0.03 to 1.5 parts by mass, and particularly preferably 0.3 to 0.7 parts by mass of one or more types selected from the group consisting of sorbic acid and its salts and solvates thereof per 1 part by mass of Ripasudil converted to its free form.

[0026] <Dissolved oxygen content> In the present invention, the dissolved oxygen content of the Ripasudil-containing aqueous composition must be 8.5 mg / L or more. As will be shown in the test examples described later, when the dissolved oxygen content of the Ripasudil-containing aqueous composition is 8.5 mg / L or more, freezing over time during low-temperature storage can occur. However, by further adding a lower aliphatic carboxylic acid to the Ripasudil-containing aqueous composition and storing the aqueous composition in a polyethylene container, such freezing over time during low-temperature storage can be prevented. Therefore, according to the means for solving the problems of the present invention, it is not necessary to incur significant effort or cost to reduce and maintain the amount of dissolved oxygen, for example, by replacing dissolved oxygen with an inert gas using nitrogen purging or by vacuum degassing, and it is possible to inexpensively and easily obtain a pharmaceutical preparation in which a ripasudil-containing aqueous composition having good storage stability and which is inhibited from freezing over time when stored at low temperatures is contained in a container.

[0027] In the present invention, the dissolved oxygen content of the Ripasudil-containing aqueous composition must be 8.5 mg / L or more (more preferably 8.5 to 13 mg / L, even more preferably 8.5 to 12 mg / L, even more preferably 8.5 to 11 mg / L, even more preferably 8.5 to 10 mg / L, and particularly preferably 8.5 to 9.5 mg / L), but is preferably 8.7 mg / L or more (more preferably 8.7 to 13 mg / L, even more preferably 8.7 to 9.5 mg / L). It is preferable that the concentration is 9 mg / L or more (more preferably 9 to 13 mg / L, even more preferably 9 to 12 mg / L, even more preferably 9 to 11 mg / L, even more preferably 9 to 10 mg / L, and particularly preferably 9 to 9.5 mg / L), and it is particularly preferable that the concentration is 9 mg / L or more (more preferably 9 to 13 mg / L, even more preferably 9 to 12 mg / L, even more preferably 9 to 11 mg / L, even more preferably 9 to 10 mg / L, and particularly preferably 9 to 9.5 mg / L).

[0028] In the present invention, the dissolved oxygen amount refers to a value measured by a membrane electrode method, particularly a polarographic method (a membrane polarographic method). Examples of dissolved oxygen meters used to measure the dissolved oxygen amount by such methods include a portable waterproof dissolved oxygen meter, model number AS720 (manufactured by AS ONE Corporation). In the present invention, the dissolved oxygen content is measured when a pharmaceutical preparation is continuously stored under specified storage conditions (storage method). That is, for example, for a pharmaceutical preparation specified as being stored at "room temperature," the dissolved oxygen content of a Ripasudil-containing aqueous composition for the pharmaceutical preparation stored at any temperature in the range of 1 to 30°C may be measured, in accordance with the definition of "room temperature" (1 to 30°C) specified in the 18th Edition of the Japanese Pharmacopoeia. If the dissolved oxygen content is 9 mg / L or more under normally expected storage conditions, freezing can be advantageously suppressed even when the pharmaceutical preparation is exposed to a low-temperature environment due to some accident during distribution or storage.

[0029] No special process is required to achieve a dissolved oxygen level of 8.5 mg / L or more in a Ripasudil-containing aqueous composition. A person skilled in the art can appropriately achieve a dissolved oxygen level of 8.5 mg / L or more by simple ingenuity in the manufacturing process typically expected for Ripasudil-containing aqueous compositions, such as adjusting the stirring speed or stirring blades so as to incorporate air during mixing of the aqueous composition. Therefore, the present invention requires significantly less labor and cost than actively or forcibly adjusting or maintaining the dissolved oxygen level at a low value. Furthermore, measures such as blowing in oxygen gas may be employed as long as they do not result in excessive labor or cost burdens. In this specification, "an aqueous composition having a dissolved oxygen content of 8.5 mg / L or more" is not limited to aqueous compositions in which the dissolved oxygen content has been intentionally "adjusted" to 8.5 mg / L or more, but also includes aqueous compositions in which the dissolved oxygen content naturally fluctuates within that range after production. These interpretation guidelines also apply to aqueous compositions in which the dissolved oxygen content is within other numerical ranges.

[0030] <Aqueous composition> In the present invention, the term "aqueous composition" refers to a composition containing at least water, and its form may be liquid (solution or suspension) or semi-solid (ointment). The water in the composition may be, for example, purified water, water for injection, sterilized purified water, etc. The water content of the aqueous composition is not particularly limited, but is preferably 5 w / v% or more, more preferably 20 w / v% or more, even more preferably 50 w / v% or more, even more preferably 90 w / v% or more, and particularly preferably 90 to 99.8 w / v%.

[0031] The aqueous composition can be made into various dosage forms according to known methods, for example, as described in the General Provisions for Preparations of the Japanese Pharmacopoeia, 18th Edition. The dosage form is not particularly limited as long as it can be accommodated in a container described below, and examples include injections, inhalation solutions, eye drops, eye ointments, ear drops, nasal solutions, enemas, topical solutions, sprays, ointments, creams, gels, oral solutions, and syrups. From the viewpoint of advantageously utilizing the pharmacological effects of Ripasudil, the dosage form is preferably an agent for ophthalmic diseases, specifically eye drops and eye ointments, with eye drops being particularly preferred.

[0032] In addition to the above, the aqueous composition may contain additives used in pharmaceuticals, quasi-drugs, etc. Examples of such additives include inorganic salts, isotonicity agents, chelating agents, stabilizers, pH adjusters, preservatives, antioxidants, thickening agents, surfactants, solubilizers, suspending agents, refreshing agents, dispersants, preservatives, oily bases, emulsion bases, water-soluble bases, etc. Specific examples of such additives include ascorbic acid, sodium bisulfite, alginic acid, sodium benzoate, benzyl benzoate, fennel oil, ethanol, ethylene-vinyl acetate copolymer, potassium chloride, calcium chloride hydrate, sodium chloride, magnesium chloride, hydrochloric acid, alkyldiaminoethylglycine hydrochloride solution, carboxyvinyl polymer, dry sodium sulfite, dry sodium carbonate, d-camphor, dl-camphor, xylitol, glycerin, gluconic acid, creatinine, chlorhexidine, chlorobutanol, and crystalline phosphoric acid. Sodium dihydrogen esters, geraniol, sodium chondroitin sulfate, titanium dioxide, gellan gum, dibutylhydroxytoluene, potassium bromide, benzododecinium bromide, sodium hydroxide, polyoxyl 45 stearate, purified lanolin, D-sorbitol, sorbitol solution, taurine, sodium bicarbonate, sodium carbonate hydrate, sodium thiosulfate hydrate, thimerosal, tyloxapol, trometamol, concentrated glycerin, concentrated mixed tocopherols, white petrolatum, peppermint water, peppermint oil, concentrated benzalkonium chloride solution 50, parahydroxybenzoic acid Ethyl parahydroxybenzoate, butyl parahydroxybenzoate, propyl parahydroxybenzoate, methyl parahydroxybenzoate, sodium hyaluronate, human serum albumin, sodium metabisulfite, phenylethyl alcohol, glucose, propylene glycol, bergamot oil, benzalkonium chloride, benzalkonium chloride solution, benzyl alcohol, benzethonium chloride, benzethonium chloride solution, borax, boric acid, povidone, polyoxyethylene (200), polyoxypropylene glycol (70), sodium polystyrene sulfonate, polysorbate 80, polio Hydroxyethylene hydrogenated castor oil 60, polyvinyl alcohol (partially saponified), d-borneol, macrogol 4000, macrogol 6000, D-mannitol, anhydrous sodium monohydrogen phosphate, anhydrous sodium dihydrogen phosphate, methanesulfonic acid, l-menthol, monoethanolamine, polyethylene glycol monostearate, eucalyptus oil, potassium iodide, sulfuric acid, oxyquinoline sulfate, liquid paraffin, ryunou, phosphoric acid, sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate monohydrate,Examples include petrolatum.

[0033] Preferred examples of additives include potassium chloride, calcium chloride hydrate, sodium chloride, magnesium chloride, glycerin, sodium hydroxide, sodium bicarbonate, sodium carbonate hydrate, concentrated glycerin, borax, boric acid, povidone, polysorbate 80, polyoxyethylene hydrogenated castor oil, polyethylene glycol monostearate, polyvinyl alcohol (partially saponified), macrogol 4000, macrogol 6000, anhydrous sodium monohydrogen phosphate, anhydrous sodium dihydrogen phosphate, monoethanolamine, phosphoric acid, sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate monohydrate, sodium hyaluronate, glucose, and l-menthol.

[0034] The aqueous composition may further contain other medicinal ingredients in addition to Ripasudil depending on the disease to be treated and the like. Examples of such active ingredients include α1 receptor blockers including bunazosin such as bunazosin hydrochloride or a salt thereof or a solvate thereof; brimonidine such as brimonidine tartrate or a salt thereof or a solvate thereof, and α2 receptor agonists including apraclonidine or a salt thereof or a solvate thereof; carteolol such as carteolol hydrochloride or a salt thereof or a solvate thereof; nipradilol or a salt thereof or a solvate thereof; timolol such as timolol maleate or a salt thereof or a solvate thereof; beta-blockers including betaxolol or a salt thereof or a solvate thereof such as betaxolol hydrochloride; levobunolol or a salt thereof or a solvate thereof such as levobunolol hydrochloride; befunolol or a salt thereof or a solvate thereof; metipranolol or a salt thereof or a solvate thereof; Rho kinase inhibitors including netarsudil or a salt thereof or a solvate thereof such as netarsudil mesylate; dorzolamide hydrochloride and the like. carbonic anhydrase inhibitors including acetazolamide or its salt or solvate thereof, brinzolamide or its salt or solvate thereof, acetazolamide or its salt or solvate thereof, dichlorphenamide or its salt or solvate thereof, methazolamide or its salt or solvate thereof; isopropyl unoprostone or its salt or solvate thereof, tafluprost or its salt or solvate thereof, travoprost or its salt or solvate thereof, bimatoprost prostaglandin F2α derivatives including prost or its salt or solvate thereof, latanoprost or its salt or solvate thereof, cloprostenol or its salt or solvate thereof, fluprostenol or its salt or solvate thereof; sympathomimetics including dipivefrin such as dipivefrin hydrochloride or its salt or solvate thereof, epinephrine, epinephrine borate, epinephrine hydrochloride or its salt or solvate thereof;Parasympathomimetics including distigmine bromide or its salts or solvates thereof, pilocarpine, pilocarpine hydrochloride, pilocarpine nitrate, or other pilocarpine or its salts or solvates thereof, and carbachol or its salts or solvates thereof; calcium antagonists including lomerizine hydrochloride or other lomerizine or its salts or solvates thereof; cholinesterase inhibitors including demecarium or its salts or solvates thereof, echothiophate or its salts or solvates thereof, and physostigmine or its salts or solvates thereof; and EP2 receptor agonists including omidenepag isopropyl or other omidenepag or its salts or solvates thereof, and one or more of these can be combined. The other active ingredient is preferably at least one selected from the group consisting of brimonidine, latanoprost, nipradilol, dorzolamide, brinzolamide, timolol, omidenepagisopropyl, and salts thereof.

[0035] The pH of the aqueous composition is not particularly limited, but is preferably 4 to 9, more preferably 4.5 to 8, and particularly preferably 5 to 7. The osmotic pressure ratio relative to physiological saline is not particularly limited, but is preferably 0.6 to 3, and particularly preferably 0.6 to 2.

[0036] <Container> In the present invention, the term "container" refers to a package that directly contains the aqueous composition. The term "container" is a concept that encompasses any of "sealed containers," "airtight containers," and "sealed containers" as defined in the General Rules of the Japanese Pharmacopoeia, 18th Edition.

[0037] The shape of the container is not particularly limited as long as it can accommodate the aqueous composition, and may be appropriately selected and set depending on the dosage form, the use of the pharmaceutical preparation, etc. Specific examples of such container shapes include containers for injections, containers for inhalants, containers for sprays, bottle-shaped containers, tube-shaped containers, containers for eye drops, containers for nasal drops, containers for ear drops, and bag-shaped containers.

[0038] In the present invention, a "polyethylene container" refers to a container in which at least the portion of the container that comes into contact with the aqueous composition is "made of polyethylene." Therefore, for example, a container having a polyethylene layer as the inner layer that comes into contact with the aqueous composition and another resin or the like laminated on the outside also falls under the category of a "polyethylene container." Here, the polyethylene is not particularly limited, and examples include low-density polyethylene (including linear low-density polyethylene), high-density polyethylene, medium-density polyethylene, etc., and one or more of these can be used in combination. In this specification, "made of polyethylene" means that at least a portion of the material contains polyethylene, and for example, a mixture of two or more resins (polymer alloy) consisting of polyethylene and a resin other than polyethylene is also included in "made of polyethylene."

[0039] It is preferable to further incorporate a substance that blocks the transmission of ultraviolet light, such as an ultraviolet absorber or an ultraviolet scattering agent, into the polyethylene container. This improves the stability of Ripasudil against light. Specific examples of such substances include titanium oxide as an ultraviolet scattering agent;Examples include zinc oxide. Examples of ultraviolet absorbers include 2-(2H-benzotriazol-2-yl)-p-cresol (e.g., Tinuvin P, manufactured by BASF), 2-(2H-benzotriazol-2-yl)-4,6-bis(1-methyl-1-phenylethyl)phenol (e.g., Tinuvin 234, manufactured by BASF), 2-(3,5-di-t-butyl-2-hydroxyphenyl)benzotriazole (e.g., Tinuvin 320, manufactured by BASF), 2-[5-chloro(2H)-benzotriazol-2-yl]-4-methyl-6-(tert-butyl)phenol (e.g., Tinuvin 326, manufactured by BASF), 2-(3,5-di-t-butyl-2-hydroxyphenyl)-5-chlorobenzotriazole (e.g., Tinuvin 327, manufactured by BASF), and 2-(2H-benzotriazol-2-yl)-4,6-di-tert-pentylphenol (e.g., Tinuvin PA328: BASF), 2-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol (e.g., Tinuvin 329: BASF), 2,2'-methylenebis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol] (e.g., Tinuvin 360: BASF), reaction products of methyl 3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionate with polyethylene glycol 300 (e.g., Tinuvin 213: BASF), 2-(2H-benzotriazol-2-yl)-6-dodecyl-4-methylphenol (e.g., Tinuvin 571: BASF), benzotriazole-based ultraviolet absorbers such as 2-(2'-hydroxy-3',5'-di-t-amylphenyl)benzotriazole, 2-[2'-hydroxy-3'-(3'',4'',5'',6''-tetrahydrophthalimidomethyl)-5'-methylphenyl]benzotriazole, and 2,2'-methylenebis[4-(1,1,3,3-tetramethylbutyl)-6-(2H-benzotriazol-2-yl)phenol];Cyanoacrylate-based UV absorbers such as 2,2-bis{[2-cyano-3,3-diphenylacryloyloxy]methyl}propane-1,3-diyl bis(2-cyano-3,3-diphenylacrylate) (e.g., Uvinul 3030 FF: BASF), ethyl 2-cyano-3,3-diphenylacrylate (e.g., Uvinul 3035: BASF), and 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (e.g., Uvinul 3039: BASF); triazine-based UV absorbers such as 2-(4,6-diphenyl-1,3,5-triazin-2-yl)-5-[(hexyl)oxy]phenol (e.g., Tinuvin 1577 ED: BASF); octabenzone (e.g., Chimassorb Benzophenone-based ultraviolet absorbers such as benzophenone-based UV absorbers such as 2,2'-dihydroxy-4,4'-dimethoxybenzophenone (e.g., Uvinul 3049: BASF), 2,2'-4,4'-tetrahydrobenzophenone (e.g., Uvinul 3050: BASF), oxybenzone, hydroxymethoxybenzophenone sulfonic acid, hydroxymethoxybenzophenone sodium sulfonate, dihydroxydimethoxybenzophenone, dihydroxydimethoxybenzophenone sodium disulfonate, dihydroxybenzophenone, and tetrahydroxybenzophenone; methyl diisopropylcinnamate, cinoxate, glyceryl di-p-methoxycinnamate mono-2-ethylhexanoate, isopropyl p-methoxycinnamate / diisopropyl cinnamate mixture, 2-ethylhexyl p-methoxycinnamate, and cinnamic acid benzyl ester. Cinnamic acid-based UV absorbers such as para-aminobenzoic acid, ethyl para-aminobenzoate, glyceryl para-aminobenzoate, amyl para-dimethylaminobenzoate, 2-ethylhexyl para-dimethylaminobenzoate, and ethyl 4-[N,N-di(2-hydroxypropyl)amino]benzoate; salicylic acid-based UV absorbers such as ethylene glycol salicylate, octyl salicylate, dipropylene glycol salicylate, phenyl salicylate, homomenthyl salicylate, and methyl salicylate; guaiazulene; 2-ethylhexyl dimethoxybenzylidene dioxoimidazolidinepropionate;Examples include 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]1,3,5-triazine; parahydroxyanisole; 4-tert-butyl-4'-methoxydibenzoylmethane; phenylbenzimidazole sulfonic acid; 2-(4-diethylamino-2-hydroxybenzoyl)-hexyl benzoate;

[0040] When a substance that blocks ultraviolet light transmission is kneaded into the container, the mixing ratio varies depending on the type of substance, etc., but may be, for example, about 0.001 to 50 mass %, preferably 0.002 to 25 mass %, and particularly preferably 0.01 to 10 mass % in the container.

[0041] It is preferable that the interior of the container is visible (observable) with the naked eye. If the interior is visible, it is possible to inspect for the presence of foreign matter during the manufacturing process of the pharmaceutical preparation, and it is possible for users of the pharmaceutical preparation to check the remaining amount of the contents (aqueous composition). Here, visibility is sufficient as long as at least a portion of the container surface is ensured (for example, even if the side of an eye drop container is obscured by a shrink film or the like, it can be said that visibility is possible as long as the bottom surface is visible). If the interior is visible from a portion of the container surface, this makes it possible to check the aqueous composition in the container.

[0042] The means for storing the aqueous composition in the container is not particularly limited, and the aqueous composition may be filled in a conventional manner according to the shape of the container.

[0043] <Pharmaceutical preparations> In the present invention, the indications for the "pharmaceutical preparation" are not particularly limited, and may be appropriately selected depending on the pharmacological action of Ripasudil, etc. Specifically, for example, ripasudil can be used as a preventive or therapeutic agent for ocular hypertension and glaucoma, based on its Rho kinase inhibitory activity and intraocular pressure-reducing activity. More specific examples of glaucoma include primary open-angle glaucoma, normal-tension glaucoma, aqueous humor overproduction glaucoma, acute angle-closure glaucoma, chronic angle-closure glaucoma, plateau iris syndrome, mixed glaucoma, steroid-induced glaucoma, lenticular capsular glaucoma, pigmentary glaucoma, amyloid glaucoma, neovascular glaucoma, and malignant glaucoma.

[0044] Furthermore, as disclosed in Japanese Patent No. 5557408, ocular fundus diseases (lesions that mainly occur in the retina and / or choroid. Specific examples thereof include fundus changes due to hypertension and arteriosclerosis, retinal vein occlusions such as central retinal artery occlusion, central retinal vein occlusion, and branch retinal vein occlusion, congenital retinal vascular abnormalities such as diabetic retinopathy, diabetic macular edema, diabetic maculopathy, Eales disease, and Coats disease, von Hippel disease, pulseless disease, macular diseases (central serous chorioretinopathy, cystoid macular edema, age-related macular degeneration, macular hole, myopic macular atrophy), and other diseases. The present invention can be used as a prophylactic or therapeutic agent for diabetic retinopathy, diabetic macular edema, or age-related macular degeneration, more preferably diabetic retinopathy, diabetic macular edema, or age-related macular degeneration, and ... retinopathy, diabetic macular edema, or age-related macular degeneration, and more preferably diabetic retinopathy, diabetic retinopathy, diabetic macular edema, or age-related macular degeneration, and more preferably diabetic retinopathy, diabetic retinopathy, diabetic macular edema, or age-related macular degeneration, and more preferably diabetic retinopathy, diabetic retinopathy, diabetic retinopathy, diabetic retinopathy, diabetic retinopathy, diabetic retinopathy, diabetic retinopathy, diabetic retinopathy, Furthermore, as disclosed in Japanese Patent No. 5657252, it can also be used as an agent for preventing and / or treating corneal endothelial disorders.

[0045] <Significance of other words> In the present invention, "low-temperature storage" means storage at a temperature lower than room temperature (1 to 30°C) that a pharmaceutical preparation may accidentally encounter during distribution or storage after production, and specifically, for example, storage at -5°C is envisaged. In the present invention, "freezing" is not necessarily limited to the case where the entire Ripasudil-containing aqueous composition is frozen, but also includes the case where only a portion of the composition is frozen. In the present invention, "suppression" with respect to freezing means that by taking the technical means disclosed in this specification, "freezing" is suppressed for a relatively longer period of time compared to when such means are not taken, or that by taking the technical means disclosed in this specification, the degree of "freezing" over the same period of time is suppressed compared to when such means are not taken (the range or extent of freezing occurring is smaller), and does not necessarily mean that the Ripasudil-containing aqueous composition will never freeze. For example, if the evaluation target contains edetic acid as a lower aliphatic carboxylic acid, and a comparison target that does not contain edetic acid but has the same components, dissolved oxygen content, etc. is prepared and stored under the same low-temperature storage conditions, this means that the evaluation target will be inhibited from "freezing" for a relatively longer period of time than the comparison target, or that the degree of "freezing" will be inhibited at the same time.

[0046] <Method for preventing freezing and method for producing pharmaceutical preparations> The present invention also relates to a method for preventing freezing of an aqueous composition during low-temperature storage, the method comprising the steps of adding lower aliphatic carboxylic acids to an aqueous composition containing Ripasudil or a salt thereof, or a solvate thereof and having a dissolved oxygen content of 8.5 mg / L or more, and placing the aqueous composition in a polyethylene container. Furthermore, the present invention also relates to a method for producing a pharmaceutical preparation that is inhibited from freezing during low-temperature storage, the method comprising the steps of adding lower aliphatic carboxylic acids to an aqueous composition that contains ripasudil, a salt thereof, or a solvate of either and has a dissolved oxygen content of 8.5 mg / L or more, and placing the aqueous composition in a polyethylene container. In the above method, the order of the step of incorporating Ripasudil into the aqueous composition, the step of incorporating a lower aliphatic carboxylic acid into the aqueous composition, and the step of placing the aqueous composition in a polyethylene container does not matter. Furthermore, the timing at which the dissolved oxygen content of the aqueous composition reaches 8.5 mg / L or more is also not particularly important, and as long as the dissolved oxygen content of the aqueous composition reaches 8.5 mg / L or more at any timing, the method can be considered as a "method for inhibiting freezing" or a "method for producing a pharmaceutical preparation" disclosed in the present specification. The meanings of other various terms, the amounts of each ingredient, etc. are all the same as those explained for the "pharmaceutical preparation" above.

[0047] The present invention discloses, for example, embodiments of the following aspects, but is not limited thereto. [1A] A pharmaceutical preparation comprising an aqueous composition containing ripasudil or a salt thereof or a solvate thereof and a lower aliphatic carboxylic acid, the aqueous composition having a dissolved oxygen content of 8.5 mg / L or more (preferably 8.7 mg / L or more, particularly preferably 9 mg / L or more), and the aqueous composition being contained in a polyethylene container. [2A] A pharmaceutical preparation comprising an aqueous composition containing ripasudil or a salt thereof or a solvate thereof and a lower aliphatic carboxylic acid, the aqueous composition having a dissolved oxygen content of 8.5 to 13 mg / L (preferably 8.7 to 13 mg / L, particularly preferably 9 to 13 mg / L), and the aqueous composition being contained in a polyethylene container. [3A] A pharmaceutical preparation comprising an aqueous composition containing ripasudil or a salt thereof or a solvate thereof and a lower aliphatic carboxylic acid, the aqueous composition having a dissolved oxygen content of 8.5 to 12 mg / L (preferably 8.7 to 12 mg / L, particularly preferably 9 to 12 mg / L), and the aqueous composition being contained in a polyethylene container. [4A] A pharmaceutical preparation comprising an aqueous composition containing ripasudil or a salt thereof or a solvate thereof and a lower aliphatic carboxylic acid, the aqueous composition having a dissolved oxygen content of 8.5 to 11 mg / L (preferably 8.7 to 11 mg / L, particularly preferably 9 to 11 mg / L), and the aqueous composition being contained in a polyethylene container. [5A] A pharmaceutical preparation comprising an aqueous composition containing ripasudil or a salt thereof or a solvate thereof and a lower aliphatic carboxylic acid, the aqueous composition having a dissolved oxygen content of 8.5 to 10 mg / L (preferably 8.7 to 10 mg / L, particularly preferably 9 to 10 mg / L), and the aqueous composition being contained in a polyethylene container. [6A] The pharmaceutical formulation according to any one of [1A] to [5A], wherein the lower aliphatic carboxylic acids are one or more selected from the group consisting of epsilon-aminocaproic acid, edetic acid, citric acid, acetic acid, sorbic acid, salts thereof, and solvates thereof. [7A] The pharmaceutical formulation according to any one of [1A] to [5A], wherein the lower aliphatic carboxylic acids are one or more selected from the group consisting of edetic acid, salts thereof, and solvates thereof. [8A] The pharmaceutical formulation according to any one of [1A] to [7A], wherein freezing of the aqueous composition is inhibited after low-temperature storage (preferably storage at -5°C, particularly preferably storage at -5°C for 2 weeks).

[0048] [1B] A method for preventing freezing of an aqueous composition during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition containing ripasudil or a salt thereof, or a solvate thereof and having a dissolved oxygen content of 8.5 mg / L or more (preferably, approximately 8.7 mg / L or more, particularly preferably, 9 mg / L or more); and placing the aqueous composition in a polyethylene container. [2B] A method for preventing freezing of an aqueous composition during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition containing ripasudil or a salt thereof, or a solvate thereof and having a dissolved oxygen content of 8.5 to 13 mg / L (preferably 8.7 to 13 mg / L, particularly preferably 9 to 13 mg / L); and placing the aqueous composition in a polyethylene container. [3B] A method for preventing freezing of an aqueous composition during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition containing Ripasudil or a salt thereof, or a solvate thereof and having a dissolved oxygen content of 8.5 to 12 mg / L (preferably 8.7 to 12 mg / L, particularly preferably 9 to 12 mg / L); and placing the aqueous composition in a polyethylene container. [4B] A method for preventing freezing of an aqueous composition during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition containing ripasudil or a salt thereof, or a solvate thereof and having a dissolved oxygen content of 8.5 to 11 mg / L (preferably 8.7 to 11 mg / L, particularly preferably 9 to 11 mg / L); and placing the aqueous composition in a polyethylene container. [5B] A method for preventing freezing of an aqueous composition during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition containing ripasudil or a salt thereof, or a solvate thereof and having a dissolved oxygen content of 8.5 to 10 mg / L (preferably 8.7 to 10 mg / L, particularly preferably 9 to 10 mg / L); and placing the aqueous composition in a polyethylene container. [6B] The method according to any one of [1B] to [5B], wherein the lower aliphatic carboxylic acids are one or more selected from the group consisting of epsilon-aminocaproic acid, edetic acid, citric acid, acetic acid, sorbic acid, salts thereof, and solvates thereof. [7B] The method according to any one of [1B] to [6B], wherein the lower aliphatic carboxylic acids are at least one selected from the group consisting of edetic acid, salts thereof, and solvates thereof.

[0049] [1C] A method for producing a pharmaceutical preparation that is inhibited from freezing during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition that contains ripasudil or a salt thereof, or a solvate thereof and has a dissolved oxygen content of 8.5 mg / L or more (preferably 8.7 mg / L or more, particularly preferably 9 mg / L or more); and placing the aqueous composition in a polyethylene container. [2C] A method for producing a pharmaceutical preparation that is inhibited from freezing during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition that contains ripasudil or a salt thereof, or a solvate of either, and that has a dissolved oxygen content of 8.5 to 13 mg / L (preferably 8.7 to 13 mg / L, particularly preferably 9 to 13 mg / L); and placing the aqueous composition in a polyethylene container. [3C] A method for producing a pharmaceutical preparation that is inhibited from freezing during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition that contains ripasudil or a salt thereof, or a solvate of either, and that has a dissolved oxygen content of 8.5 to 12 mg / L (preferably 8.7 to 12 mg / L, particularly preferably 9 to 12 mg / L); and placing the aqueous composition in a polyethylene container. [4C] A method for producing a pharmaceutical preparation that is inhibited from freezing during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition that contains ripasudil or a salt thereof, or a solvate of either, and that has a dissolved oxygen content of 8.5 to 11 mg / L (preferably 8.7 to 11 mg / L, particularly preferably 9 to 11 mg / L); and placing the aqueous composition in a polyethylene container. [5C] A method for producing a pharmaceutical preparation that is inhibited from freezing during low-temperature storage, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition that contains ripasudil or a salt thereof, or a solvate of either, and that has a dissolved oxygen content of 8.5 to 10 mg / L (preferably 8.7 to 10 mg / L, particularly preferably 9 to 10 mg / L); and placing the aqueous composition in a polyethylene container. [Example]

[0050] The present invention will now be further described with reference to examples, but the present invention is not limited to these examples. In the following test examples, Ripasudil monohydrochloride dihydrate can be produced, for example, by the method described in WO 2006 / 057397.

[0051] [Test Example 1] Preservation test Part 1 An aqueous composition containing the ingredients and amounts shown in Table 1 in 100 mL was prepared by a conventional method, and then the amount of dissolved oxygen was adjusted as shown in Table 1 by blowing in nitrogen gas, oxygen gas, or air while measuring and monitoring the amount of dissolved oxygen. The aqueous composition with an adjusted dissolved oxygen content was placed in an eye drop container made of polyethylene (PE), polypropylene (PP), or glass to prepare a pharmaceutical preparation. The amount of dissolved oxygen was measured at an ambient temperature of 25°C using a dissolved oxygen meter (portable waterproof dissolved oxygen meter, model number AS720, manufactured by AS ONE Corporation).

[0052] Each of the obtained pharmaceutical preparations was stored at -5°C for 2 weeks, and the presence or absence of freezing of the aqueous composition in the container after storage was visually evaluated. Cases where no freezing occurred were evaluated as ◯, and cases where freezing occurred were evaluated as ×. Furthermore, in cases where freezing occurred, comments were made about the appearance. The results are shown in Table 1. The amount of dissolved oxygen was rounded to one decimal place.

[0053] [Table 1]

[0054] As shown in the results in Table 1, when a Ripasudil-containing aqueous composition with a dissolved oxygen content of 8.5 mg / L or more, specifically 9 mg / L, was placed in a polyolefin resin container (Examples 1 and 2), freezing of the entire aqueous composition was observed after storage at -5°C for 2 weeks. On the other hand, when a Ripasudil-containing aqueous composition with a dissolved oxygen content of less than 8.5 mg / L (3 or 6 mg / L) was placed in a polyolefin resin container (Examples 3 to 6), no freezing was observed after similar storage. This revealed that such freezing depends on the dissolved oxygen content in the Ripasudil-containing aqueous composition and is a phenomenon that occurs when the dissolved oxygen content is 8.5 mg / L or more. Furthermore, when aqueous compositions containing no Ripasudil and having a dissolved oxygen content of 8.5 mg / L or more were placed in polyolefin resin containers (Examples 7 and 8), and when aqueous compositions containing Ripasudil and having a dissolved oxygen content of 8.5 mg / L or more were placed in glass containers (Example 9), no freezing was observed after low-temperature storage. This demonstrates that such freezing is due to the aqueous compositions containing Ripasudil and being placed in polyolefin resin containers.

[0055] From the above, it was found that when the dissolved oxygen content of a Ripasudil-containing aqueous composition stored in a polyolefin resin container is high, at 8.5 mg / L or more, the phenomenon of freezing specifically occurs when stored at low temperatures.

[0056] [Test Example 2] Preservation test Part 2 An aqueous composition containing the ingredients and amounts shown in Table 2 in 100 mL was prepared by a conventional method, and then the amount of dissolved oxygen was adjusted as shown in Table 2 by blowing in nitrogen gas, oxygen gas, or air while measuring and monitoring the amount of dissolved oxygen. The aqueous composition with an adjusted dissolved oxygen content was placed in a polyethylene (PE) or polypropylene (PP) eye drop container to prepare a pharmaceutical preparation. The amount of dissolved oxygen was measured at an ambient temperature of 25°C using a dissolved oxygen meter (portable waterproof dissolved oxygen meter, model number AS720, manufactured by AS ONE Corporation).

[0057] Each of the obtained pharmaceutical preparations was stored at -5°C for 2 weeks, and after storage, the presence or absence of freezing of the aqueous composition in the container was evaluated in the same manner as in Test Example 1. The results are shown in Table 2. The amount of dissolved oxygen was rounded to one decimal place.

[0058] [Table 2]

[0059] As shown in Table 2, freezing of the entire aqueous composition was confirmed after 2 weeks of storage at −5° C. in both the pharmaceutical preparation of Comparative Example 1, in which a Ripasudil-containing aqueous composition having a dissolved oxygen content of 8.5 mg / L or more, specifically 9 mg / L, was contained in a polyethylene container, and the pharmaceutical preparation of Comparative Example 2, in which a Ripasudil-containing aqueous composition having a dissolved oxygen content of 8.5 mg / L or more further contained sodium edetate hydrate and the aqueous composition was contained in a polypropylene container. On the other hand, no freezing was confirmed after similar storage in the pharmaceutical preparation of Example 1, in which a Ripasudil-containing aqueous composition having a dissolved oxygen content of 8.5 mg / L or more further contained sodium edetate hydrate and the aqueous composition was contained in a polyethylene container. From the above, it has become clear that when a Ripasudil-containing aqueous composition having a dissolved oxygen content of 8.5 mg / L or more is added with lower aliphatic carboxylic acids represented by one or more selected from the group consisting of edetic acid and its salts and their solvates, and the aqueous composition is contained in a polyolefin resin container, especially a polyethylene container, freezing during low-temperature storage can be relatively suppressed compared to when the requirements are not met.

[0060] Furthermore, when one or more lower aliphatic carboxylic acids selected from the group consisting of epsilon-aminocaproic acid, citric acid, acetic acid, sorbic acid, salts thereof, and solvates thereof are used instead of one or more lower aliphatic carboxylic acids selected from the group consisting of edetic acid, salts thereof, and solvates thereof, a similar effect of inhibiting freezing during low-temperature storage can be confirmed.

[0061] [Test Example 3] Preservation test No. 3 An aqueous composition containing the ingredients and amounts shown in Table 3 in 100 mL was prepared by a conventional method, and then the amount of dissolved oxygen was adjusted as shown in Table 3 by blowing in nitrogen gas, oxygen gas, or air while measuring and monitoring the amount of dissolved oxygen. The aqueous composition with an adjusted dissolved oxygen content was placed in a polyethylene (PE) eye drop container to prepare a pharmaceutical preparation. The amount of dissolved oxygen was measured at an ambient temperature of 25°C using a dissolved oxygen meter (portable waterproof dissolved oxygen meter, model number AS720, manufactured by AS ONE Corporation).

[0062] Each of the obtained pharmaceutical preparations was stored at -5°C for 2 weeks, and after storage, the presence or absence of freezing of the aqueous composition in the container was evaluated in the same manner as in Test Example 1. The results are shown in Table 3. The amount of dissolved oxygen was rounded to one decimal place.

[0063] [Table 3]

[0064] As shown in Table 3, in the pharmaceutical preparations of Examples 2 and 3, in which sodium edetate hydrate was added to a Ripasudil-containing aqueous composition having a dissolved oxygen content of 11.0 mg / L or 13.0 mg / L, respectively, and the aqueous compositions were contained in polyethylene containers, no freezing was observed after storage at -5°C for 2 weeks, as with the pharmaceutical preparation of Example 1.

[0065] [Manufacturing Examples 1 to 5] An aqueous composition containing the ingredients and amounts shown in Table 4 in 100 mL was prepared by a conventional method, and then the amount of dissolved oxygen was adjusted to the level shown in Table 3 by blowing in nitrogen gas, oxygen gas, or air while measuring and monitoring the amount of dissolved oxygen. This was then placed in a polyethylene eye drop container to obtain the pharmaceutical preparations of Preparation Examples 1 to 5.

[0066] [Table 4]

[0067] [Manufacturing Examples 6 to 10] An aqueous composition containing the ingredients and amounts shown in Table 5 in 100 mL was prepared by a conventional method, and then the amount of dissolved oxygen was adjusted to the level shown in Table 4 by blowing in nitrogen gas, oxygen gas, or air while measuring and monitoring the amount of dissolved oxygen. This was then placed in a polyethylene eye drop container to obtain the pharmaceutical preparations of Preparation Examples 6 to 10.

[0068] [Table 5]

[0069] [Manufacturing Examples 11 to 15] An aqueous composition containing the ingredients and amounts shown in Table 6 in 100 mL was prepared by a conventional method, and then the dissolved oxygen content was adjusted to the level shown in Table 5 by blowing in nitrogen gas, oxygen gas, or air while measuring and monitoring the dissolved oxygen content. This was then placed in a polyethylene eye drop container to obtain the pharmaceutical preparations of Preparation Examples 11 to 15.

[0070] [Table 6]

[0071] [Manufacturing Examples 16-20] An aqueous composition containing the ingredients and amounts shown in Table 7 in 100 mL was prepared by a conventional method, and then the amount of dissolved oxygen was adjusted to the level shown in Table 6 by blowing in nitrogen gas, oxygen gas, or air while measuring and monitoring the amount of dissolved oxygen. This was then placed in a polyethylene eye drop container to obtain the pharmaceutical preparations of Preparation Examples 16 to 20.

[0072] [Table 7]

[0073] [Manufacturing Examples 21-25] An aqueous composition containing the ingredients and amounts shown in Table 8 in 100 mL was prepared by a conventional method, and then the amount of dissolved oxygen was adjusted to the level shown in Table 7 by blowing in nitrogen gas, oxygen gas, or air while measuring and monitoring the amount of dissolved oxygen. This was then placed in a polyethylene eye drop container to obtain the pharmaceutical preparations of Preparation Examples 21 to 25.

[0074] [Table 8]

[0075] [Manufacturing Examples 26-30] An aqueous composition containing the ingredients and amounts shown in Table 9 in 100 mL was prepared by a conventional method, and then the dissolved oxygen content was adjusted to the level shown in Table 8 by blowing in nitrogen gas, oxygen gas, or air while measuring and monitoring the dissolved oxygen content. This was then placed in a polyethylene eye drop container to obtain the pharmaceutical preparations of Preparation Examples 26 to 30.

[0076] [Table 9] [Industrial Applicability]

[0077] According to the present invention, a pharmaceutical preparation having excellent storage stability can be provided, and can be suitably used in the pharmaceutical industry and the like.

Claims

1. A pharmaceutical preparation comprising an aqueous composition containing Ripasudil or a salt thereof or a solvate thereof and a lower aliphatic carboxylic acid, the composition having a dissolved oxygen content of 8.5 mg / L or more, and the aqueous composition being contained in a polyethylene container.

2. 2. The pharmaceutical preparation according to claim 1, wherein the aqueous composition has a dissolved oxygen content of 8.5 to 13 mg / L.

3. 2. The pharmaceutical preparation according to claim 1, wherein the aqueous composition has a dissolved oxygen content of 8.5 to 12 mg / L.

4. 2. The pharmaceutical preparation according to claim 1, wherein the aqueous composition has a dissolved oxygen content of 8.5 to 11 mg / L.

5. 2. The pharmaceutical formulation according to claim 1, wherein the lower aliphatic carboxylic acids are at least one selected from the group consisting of epsilon-aminocaproic acid, edetic acid, citric acid, acetic acid, sorbic acid, salts thereof, and solvates thereof.

6. 2. The pharmaceutical preparation according to claim 1, wherein the lower aliphatic carboxylic acid is at least one member selected from the group consisting of edetic acid, salts thereof, and solvates thereof.

7. A method for inhibiting freezing of an aqueous composition, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition containing Ripasudil or a salt thereof, or a solvate thereof, and having a dissolved oxygen content of 8.5 mg / L or more; and placing the aqueous composition in a polyethylene container.

8. 8. The method for inhibiting freezing of an aqueous composition according to claim 7, wherein the amount of dissolved oxygen in the aqueous composition is 8.5 to 13 mg / L.

9. 8. The method for inhibiting freezing of an aqueous composition according to claim 7, wherein the amount of dissolved oxygen in the aqueous composition is 8.5 to 12 mg / L.

10. 8. The method for inhibiting freezing of an aqueous composition according to claim 7, wherein the amount of dissolved oxygen in the aqueous composition is 8.5 to 11 mg / L.

11. The method for suppressing freezing of an aqueous composition according to claim 7, wherein the lower aliphatic carboxylic acid is at least one member selected from the group consisting of epsilon-aminocaproic acid, edetic acid, citric acid, acetic acid, sorbic acid, salts thereof, and solvates thereof.

12. 8. The method for inhibiting freezing of an aqueous composition according to claim 7, wherein the lower aliphatic carboxylic acid is at least one member selected from the group consisting of edetic acid, salts thereof, and solvates thereof.

13. A method for producing a pharmaceutical preparation in which freezing of the aqueous composition is inhibited, comprising the steps of: adding lower aliphatic carboxylic acids to an aqueous composition containing Ripasudil or a salt thereof, or a solvate thereof and having a dissolved oxygen content of 8.5 mg / L or more; and placing the aqueous composition in a polyethylene container.

14. The method for producing a pharmaceutical preparation in which freezing of the aqueous composition is inhibited according to claim 13, wherein the amount of dissolved oxygen in the aqueous composition is 8.5 to 13 mg / L.

15. The method for producing a pharmaceutical preparation in which freezing of the aqueous composition is inhibited according to claim 13, wherein the amount of dissolved oxygen in the aqueous composition is 8.5 to 12 mg / L.

16. The method for producing a pharmaceutical preparation in which freezing of the aqueous composition is inhibited according to claim 13, wherein the amount of dissolved oxygen in the aqueous composition is 8.5 to 11 mg / L.

17. The method for producing a pharmaceutical formulation in which freezing of the aqueous composition is inhibited according to claim 13, wherein the lower aliphatic carboxylic acid is at least one selected from the group consisting of epsilon-aminocaproic acid, edetic acid, citric acid, acetic acid, sorbic acid, salts thereof, and solvates thereof.

18. 14. The method for producing a pharmaceutical preparation in which freezing of the aqueous composition is inhibited according to claim 13, wherein the lower aliphatic carboxylic acid is at least one member selected from the group consisting of edetic acid, salts thereof, and solvates thereof.

Images